Clinical Scorecard: Real-World Data Supports Uveal Melanoma Test Combo
At a Glance
| Category | Detail |
|---|---|
| Condition | Uveal Melanoma |
| Key Mechanisms | Combination of PRAME status and DecisionDx-UM gene expression profile test for metastatic risk stratification. |
| Target Population | Patients diagnosed with uveal melanoma. |
| Care Setting | Ocular oncology practices in the United States. |
Key Highlights
- PRAME status enhances DecisionDx-UM test's predictive ability for metastasis.
- Three-year melanoma-specific survival rates vary significantly by tumor class and PRAME status.
- Class 2/PRAME-positive tumors have a hazard ratio of 25.3 for melanoma-specific death compared to Class 1/PRAME-negative.
Guideline-Based Recommendations
Diagnosis
- Use DecisionDx-UM test for risk stratification in uveal melanoma.
Management
- Consider PRAME status as an adjunct biomarker for assessing metastatic risk.
Monitoring & Follow-up
- Continue evaluating combined biomarker approach with follow-up data.
Risks
- Higher risk of melanoma-specific death in Class 2/PRAME-positive tumors.
Patient & Prescribing Data
Approximately 80% of newly diagnosed uveal melanoma patients in the US.
DecisionDx-UM is widely used and recommended by NCCN guidelines and AJCC staging manual.
Clinical Best Practices
- Incorporate PRAME testing in conjunction with DecisionDx-UM for improved risk stratification.
- Utilize real-world data to inform clinical decision-making.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.